Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Aug 14;45(8):713-726.
doi: 10.3760/cma.j.cn121090-20240611-00217.

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

[Article in Chinese]
Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association
Practice Guideline

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

[Article in Chinese]
Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Chronic graft-versus-host disease (cGVHD) is a common and severe complication following allogeneic hematopoietic stem cell transplantation, which significantly impacts patients' survival and quality of life. In recent years, notable progress has been made in the diagnosis, prevention, and treatment of cGVHD, driven by the emergence of novel therapies such as targeted drugs and the advancement of clinical research. This consensus, based on the latest developments in cGVHD research and growing data from evidence-based medicine, has been revised and updated from the "Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)" to better guide clinical practice.

慢性移植物抗宿主病（cGVHD）是异基因造血干细胞移植后常见且严重的并发症，严重影响患者的生存率和生活质量。近年来，随着新型靶向药物等新疗法的出现及临床研究的不断推进，cGVHD在诊断、预防、治疗等方面取得了显著进步。基于近年来cGVHD研究新进展及逐渐增多的循证医学证据，本共识在《慢性移植物抗宿主病（cGVHD）诊断与治疗中国专家共识（2021年版）》基础上进行了修订及更新，以更好地指导临床实践。.

PubMed Disclaimer

Figures

图1
图1. 慢性移植物抗宿主病（cGVHD）的诊治流程
注 二线治疗具体药物根据病情个体化选择
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Xu LP, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J] J Hematol Oncol. 2018;11(1):33. doi: 10.1186/s13045-018-0564-x. - DOI - PMC - PubMed
    1. Wang Y, Chen H, Chen J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China[J] Cancer Lett. 2018;438:63–75. doi: 10.1016/j.canlet.2018.08.030. - DOI - PubMed
    1. 王 茜茜, 张 荣莉, 韩 明哲. 慢性移植物抗宿主病发病机制研究进展[J] 中华血液学杂志. 2017;38(2):167–171. doi: 10.3760/cma.j.issn.0253-2727.2017.02.017. - DOI
    2. Wang QQ, Zhang RL, Han MZ. Advances in the pathogenesis of chronic graft versus host disease[J] Chin J Hematol. 2017;38(2):167–171. doi: 10.3760/cma.j.issn.0253-2727.2017.02.017. - DOI - PMC - PubMed
    1. Li XP, Gao QG, Feng YM, et al. Developing role of B cells in the pathogenesis and treatment of chronic GVHD[J] Br J Haematol. 2019;184(3):323–336. doi: 10.1111/bjh.15719. - DOI - PMC - PubMed
    1. Peng Y, Chen X, Liu Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10[J] Leukemia. 2015;29(3):636–646. doi: 10.1038/leu.2014.225. - DOI - PubMed